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Juan Xiao1,2,3†, Wenwei Liu1†, Yingyu Chen2* and Wenbin Deng1,3*Abstract
Background: In multiple sclerosis (MS) and its widely used animal model, experimental autoimmune encephalomyelitis
(EAE), autoreactive T cells contribute importantly to central nervous system (CNS) tissue damage and disease
progression. Promoting apoptosis of autoreactive T cells may help eliminate cells responsible for inflammation and may
delay disease progression and decrease the frequency and severity of relapse. Programmed cell death 5 (PDCD5) is a
protein known to accelerate apoptosis in response to various stimuli. However, the effects of recombinant human
PDCD5 (rhPDCD5) on encephalitogenic T cell-mediated inflammation remain unknown.
Methods: We examined the effects of intraperitoneal injection of rhPDCD5 (10 mg/kg) on EAE both prophylactically
(started on day 0 post-EAE induction) and therapeutically (started on the onset of EAE disease at day 8), with both of the
treatment paradigms being given every other day until day 25. Repeated measures two-way analysis of variance was
used for statistical analysis.
Results: We showed that the anti-inflammatory effects of rhPDCD5 were due to a decrease in Th1/Th17 cell frequency,
accompanied by a reduction of proinflammatory cytokines, including IFN-γ and IL-17A, and were observed in both
prophylactic and therapeutic regimens of rhPDCD5 treatment in EAE mice. Moreover, rhPDCD5-induced apoptosis of
myelin-reactive CD4+ T cells, along with the upregulation of Bax and downregulation of Bcl-2, and with activated
caspase 3.
Conclusions: Our data demonstrate that rhPDCD5 ameliorates the autoimmune CNS disease by inhibiting Th1/Th17
differentiation and inducing apoptosis of predominantly pathogenic T cells. This study provides a novel mechanism to
explain the effects of rhPDCD5 on neural inflammation. The work represents a translational demonstration that rhPDCD5
has prophylactic and therapeutic properties in a model of multiple sclerosis.
Keywords: rhPDCD5, Th1/T17, Multiple sclerosisIntroduction
MS is an inflammatory neurodegenerative disease caused
by autoimmune attack against myelin [1]. Impaired
apoptotic mechanisms contribute to the production and
release of autoreactive T cells that lead to inflammatory
demyelination lesions in MS and EAE [2–4]. The* Correspondence: yingyu_chen@bjmu.edu.cn; wbdeng@ucdavis.edu
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disease [5, 6], and the T cells become more resistant to
pro-apoptotic stimuli that trigger caspase activation [7, 8].
The reasons for the decreased susceptibility of activated T
cells to apoptosis in MS and EAE are not well understood.
EAE is a CD4+ T cell-mediated autoimmune disease
model of MS [9, 10]. Both Th1 and Th17 lineages of CD4+
T cells are major effector cells responsible for the develop-
ment of EAE [11–15]. In EAE, T cell apoptosis is thought
to be critical for disease recovery [16]. RNAi-mediated
knockdown of T-bet, a key regulator of the proinflamma-
tory immune response, ameliorates EAE and limits differ-
entiation of both autoreactive Th1 and Th17 cells [17].le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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EAE animals is associated with decreased inflammation
and reduced disease severity [18]. Administration of apop-
tosis inhibitors results in impaired recovery and earlier re-
lapse in EAE by suppressing apoptotic death of
inflammatory cells in the CNS [19]. Moreover, osteopontin
exacerbates EAE symptoms by enhancing the survival of
activated T cells and by decreasing levels of pro-apoptotic
members of the Bcl-2 family [20]. In contrast, factors in-
creasing the apoptotic sensitivity of T cells reduce disease
severity of EAE [21, 22]. Taken together, these findings sug-
gest that promoting the elimination of autoreactive T cells
by apoptosis is a possible strategy for treating MS.
Programmed cell death 5 (PDCD5) is initially identified
as a gene upregulated in cells undergoing apoptosis [23]
and promotes apoptosis in response to various stimuli [24,
25]. In cells undergoing apoptosis, PDCD5 is upregulated
and rapidly translocates from the cytoplasm to nucleus
[26]. PDCD5 interacts with a histone acetyl transferase,
TIP60, and functions as a co-activator to promote apoptosis
via the TIP60-p53 signaling pathway [27]. PDCD5 also in-
teracts with p53 and is a positive regulator of p53 gene ex-
pression during cell cycle [28]. The recombinant human
PDCD5 (rhPDCD5) protein enters cells through clathrin-
independent endocytosis and then promotes apoptotic ac-
tivity [29]. It has been shown that rhPDCD5 sensitizes
chondrosarcomas to cisplatin chemotherapy [30], myeloge-
nous leukemia cells to idarubicin (IDR) and aracytidine
(Ara-C) chemotherapy [31], and breast cancer cells to pacli-
taxel chemotherapy [32] by inducing tumor cell apoptosis.
We have shown that PDCD5 transgenic mice develop
less severe EAE, accompanied by decreased Th1 and Th17
cells following myelin oligodendrocyte glycoprotein peptide
(MOG35–55) immunization [33]. In the present study, we
examine whether exogenous rhPDCD5 induces apoptosis
of myelin-reactive T cells and exerts anti-inflammatory ef-
fects against EAE. We show anti-inflammatory activities of
prophylactic and therapeutic administrations of rhPDCD5
in EAE mice. Our results demonstrate that both rhPDCD5
regimens decrease Th1/Th17 cell frequency and induce
apoptosis of encephalitogenic T cells, indicating that
rhPDCD5 is an effective inhibitor of inflammation in an
established model of MS in mice.
Materials and methods
Chemicals and reagents
Antibodies for detection of the following targets were pur-
chased as indicated: caspase-3 from Cell Signaling Technol-
ogy; Bax (ab7977) from Abcam; Bcl-2 from BD
Biosciences-Pharmingen; and actin from Sigma. Phorbol
12-myristate 13-acetate (PMA), ionomycin, and OVA were
purchased from Sigma. Mouse Th1/Th17 phenotyping kit
and Perm/Fix solution were purchased from BD Biosci-
ences (USA). IFN-γ and IL-17A ELISA kits were obtainedfrom eBioscience (USA). FITC-anti-CD4 was obtained from
Sungene Biotech (Tianjin, china). The MOG35-55 peptide
(MEVGWYRSPFSRVVHLYRNGK) was synthesized by
Chinese Peptide Company (Hangzhou, China). DyLight
800/DyLight 680-conjugated secondary antibodies against
mouse or rabbit IgG were purchased from Rockland Im-
munochemicals (USA). Recombinant human PDCD5 pro-
tein was supplied by Beijing Biosea Biotechnology Co. The
endotoxin activity of the rhPDCD5 protein received was
<10 EU/mg as detected using the limulus amebocyte lysate
assay, and the purity of the rhPDCD5 protein was >95 %.
Induction, clinical evaluation, and treatment protocols of EAE
C57BL/6 mice were bred at the Experimental Animal
Center, Peking University Health Sciences Center (Beijing,
China). All experimental procedures and protocols were
approved by the Peking University Animal Ethics Com-
mittee and were performed in accordance with the institu-
tional guidelines and regulations.
EAE was induced by MOG35–55 in female mice used
between 8 and 10 weeks of age. Briefly, each mouse was
immunized subcutaneously with 300 μg of MOG35–55
emulsified with an equal volume of complete Freund’s
adjuvant (CFA, total 300 mg of Mycobacterium tubercu-
losis, strain H37RA, Difco, USA) and then injected to
the caudal vein with 200 ng of pertussis toxin (dissolved
in 200-μl PBS, List Biological Laboratories, USA) at the
time of immunization and 2 days later. Mice were exam-
ined for clinical scoring daily by the same, blind investi-
gator for 25 days after immunization. Neurological
assessments were reported using a 5-point standardized
rating scale to evaluate motor deficit as follows: 0, no
deficit; 1, tail paralysis; 2, incomplete hind limb paralysis;
3, complete hind limb paralysis; 4, complete hind limb
paralysis and partial forelimb paralysis; 5, moribund state
or death. Scoring was performed in a blinded fashion.
OVA or rhPDCD5 was dissolved in PBS made up to 2
mg/ml. Prophylactic treatment with rhPDCD5 (10 mg/kg,
injected intraperitoneally, i.p.) or OVA (10 mg/kg, i.p.)
started on day 0 post-EAE induction and continued every
other day until day 25. Therapeutic treatment with
rhPDCD5 (10 mg/kg, i.p.) or OVA (10 mg/kg, i.p.) started
at the onset of EAE disease (day 8 was the average day of
onset of disease) and was given every other day until day 25.
For adoptive transfer of EAE, donor mice were primed by
immunization with MOG35–55 emulsified with CFA. After
12 days post-immunization, draining lymph node (DLN)
lymphocytes and splenocytes were harvested and cultured
at 5 × 106/ml in RPMI 1640 for 48 h with 20 μg/ml
MOG35–55 together with rhPDCD5 (20 μg/ml), and then
CD4+ T cells were isolated. Recipient mice were sublethally
irradiated, then 3 × 106/ml CD4+ T cells were transferred
intravenously to recipient mice, and pertussis toxin (200
ng) was injected at days 0 and 2 post-CD4+ T cell transfer.
Xiao et al. Journal of Neuroinflammation  (2015) 12:117 Page 3 of 11Histological examination
Histological analysis was performed on spinal cords ob-
tained from EAE treated with rhPDCD5 and OVA at day
25 after immunization. Following anesthesia with intraper-
itoneal administration of pentobarbital, each mouse was
perfused with 4 % paraformaldehyde in 0.1 M phosphate
buffer. Each spinal cord was carefully removed and
immersed in the same fixative. The cervical, thoracic, and
lumbar segments of each spinal cord were embedded in
paraffin. Five-mm-thick sections were prepared and
stained with hematoxylin-eosin (H&E). Semiquantitative
histological evaluation for inflammation was scored in a
blinded fashion as follows: 0, no inflammation; 1, immune
cellular infiltration only in the perivascular area and men-
inges; 2, mild cellular infiltration in parenchyma; 3, mod-
erate cellular infiltration in parenchyma; 4, severe cellular
infiltration in parenchyma.
Flow cytometry analysis
The DLNs from EAE mice treated with rhPDCD5 and
OVA were harvested, and a single cell suspension was pre-
pared. To quantify the number of Th1/Th17 cells, cells were
stimulated with PMA and ionomycin in the presence of
brefeldin A for 5 h. Subsequently, cells were surface-stained
with anti CD4-FITC, permeabilized with Perm/Fix solution
and stained with anti-IFN-γ-PE and anti-IL-17A-PE.
Isotype-matched IgG was used as a negative control. The
stained cells were analyzed by FACSCalibur using CellQuest
software (BD Biosciences, USA). For detection of apoptosis,
lymphocytes from DLNs of EAE mice were harvested and
stimulated with or without of 20 μg/ml of MOG35–55 pep-
tide. After 48 h, cells were collected and stained with anti-
CD4-PE/AnnexinV-FITC, and percentages of CD4+
Annexin V+ cells were analyzed by flow cytometry. For de-
tecting the promoting apoptosis effect of rhPDCD5 in vitro,
lymphocytes from DLNs of EAE mice were stimulated with
MOG35–55 and increasing concentration of rhPDCD5. After
48 h, cells were stained with anti-CD4-PE/AnnexinV-FITC,
and percentages of Annexin V+ cells gated on CD4+ T cells
were analyzed by flow cytometry.
Lymphocyte proliferation assay and detection of
cytokines in the supernatant and serum
To investigate differences in lymphocyte responses to
MOG35–55 between OVA and rhPDCD5-treated EAE mice,
lymphocytes from DLNs at day 25 were seeded at 5 × 105
cells/well in 96-well plates with RPMI 1640 containing 10
% fetal calf serum (FCS) and stimulated with or without 20
μg/ml of MOG35–55 peptide. After 48 h, cells were pulsed
with 1 μCi/well [3H]-thymidine (MP Biomedicals, USA)
and incubated for an additional 8 h. The results are
expressed as mean [3H] thymidine incorporation (cpm) ±
SEM. For detecting cytokines in culture supernatants, lym-
phocytes were treated as described above. Concentrationsof cytokines in the cell supernatant were measured using
ELISA kit according to the manufacturer’s instruction. The
cytokine concentration in individual mouse serum samples
was also detected with the same method.
Western blot analysis
For experiments of Western blot analysis, lymphocytes from
DLNs at day 25 were collected and lysed in lysis buffer (300
mM NaCl, 50 mM Tris pH 8.0, 0.4 % NP-40, 10 mM
MgCl2, and 2.5 mM CaCl2) supplemented with protease in-
hibitors (Complete mini EDTA-free; Roche Diagnostics,
Mannheim, Germany). After centrifugation, the supernatant
was measured using the BCA protein assay reagent (Pierce,
Rockford, IL, USA). Then, 1 μg of total cell extract protein
was loaded onto 12.5 % SDS-PAGE, transferred to nitrocel-
lulose membrane (Amersham Pharmacia Biotech, Little
Chalfont, UK), blocked by incubation with 5 % non-fat milk
in TBS-T buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl,
and 0.1 % Tween-20) for 1 h, and blotted against the differ-
ent proteins using specific antibodies: anti-caspase-3, anti-
Bax, anti-Bcl-2, and anti-actin. After washings with TBS, the
protein bands were visualized using DyLight 800/DyLight
680-conjugated secondary antibodies, and the infrared
fluorescence image was obtained using an Odyssey infrared
imaging system (LI-COR Biosciences, USA).
Quantitative RT-PCR analysis of PDCD5 expression
Total RNA was extracted from DLNs using Trizol accord-
ing to the manufacturer’s instructions, and 10 μg RNA was
reverse-transcribed to cDNA using the cDNA synthesis kit.
PCR was performed using PDCD5 specific primers (5′-
CCGAAGCGATTCCAACCGA-3′ and 5′-CTGTCCTAG
ACACTGCTCCG-3′) to generate a 517 bp product over
35 cycles and GAPDH specific primers (5′-CAAGGTCAT
CCATGACAACTTTG-3′ and 5′-GTCCACCACCCTGT
TGCTGTAG-3′) to generate a 496 bp product over 25 cy-
cles of 95 °C for 3 min, 95 °C for 30 s, 58 °C for 30 s, 72 °C
for 30 s and 72 °C for 5 min.
Statistical analysis
For comparisons of the clinical scores of EAE between
the OVA- and rhPDCD5-treated animals, repeated mea-
sures two-way analysis of variance (ANOVA) followed
by Bonferroni post hoc tests were performed to compare
replicate by time. Differences in cell frequency and cyto-
kine production between OVA and rhPDCD5-treated
mice were evaluated with Student t-test. A value of
p < 0.05 was considered significant.
Results
rhPDCD5 treatment attenuates EAE development and
protects against spinal cord destruction
C57BL/6 mice were immunized as described in Materials
and methods. Ovalbumin (OVA, serving as a negative
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each mouse every other day. Mice treated with rhPDCD5
every other day starting at day 0 on the onset of disease in-
duction showed a delayed disease onset and developed less
severe EAE than control mice treated by OVA (Fig. 1a).
rhPDCD5 injected therapeutically every other day, starting
at the onset of EAE disease symptoms (day 8), developed a
similar degree of EAE from day 8 to 14 but a faster recov-
ery compared with that seen in OVA-treated EAE mice
(Fig. 1b). Histological examinations of the spinal cord tis-
sue collected at day 25 after immunization revealed that
minimal lymphocyte infiltration was found in the CNS of
mice treated with rhPDCD5 both prophylactically (Fig. 1c)
and therapeutically (Fig. 1d), as compared to OVA-treated
mice, and the effects of the prophylactic rhPDCD5 regi-
men were better than the therapeutic regimen.
rhPDCD5 treatment inhibits IFN-γ and IL-17A production
in EAE mice
To investigate the immunological mechanisms associ-
ated with the reduced severity of EAE in the rhPDCD5-
treated mice, serum samples and DLNs were collected at
25 days after immunization. Cytokine levels in the serum
samples were measured by ELISA. Both prophylactic
and therapeutic rhPDCD5 treatment of EAE miceFig. 1 rhPDCD5 treatment attenuates EAE development and protects spi
(10 mg/kg i.p.) a prophylactically every other day starting on day 0 follow
of EAE disease (day 8) were monitored daily for mean clinical score. Thre
from mice treated with OVA (n = 10) or rhPDCD5 (n = 10). Statistical analy
followed by Bonferroni post hoc tests to compare replicate by time. *P <
and semiquantitative histological evaluation for inflammation in EAE mice
and therapeutically stained with H&E are shown. *P < 0.05, **P < 0.005produced significantly reduced amounts of serum IFN-γ
and IL-17A compared with OVA-treated EAE mice
(Fig. 2a, b). We then examined the cytokine production
by the DLN cells ex vivo. Single cell suspensions were
cultured in the presence or absence of MOG35–55 for 48
h, and the supernatants were harvested and analyzed by
ELISA for IFN-γ and IL-17A. Cells from EAE mice
treated with rhPDCD5 prophylactically and therapeutic-
ally produced significantly less IFN-γ and IL-17A in
response to MOG35–55 compared with cells from OVA-
treated mice (Fig. 2c, d). These results therefore indicate
that rhPDCD5 promotes downregulation of the inflam-
matory Th1/Th17 response.
rhPDCD5 treatment reduces Th1/Th17 response in vivo
Inflammatory T cells such as Th1/Th17 cells are thought
to play a critical role in the development of EAE. Next, we
examined the cellular phenotypes of EAE mice treated with
rhPDCD5. Single cell suspensions were prepared from the
DLNs of EAE mice 25 day after immunization as described
above and stained for cell surface and intracellular markers
by FACS. Consistent with the cytokine profile observed
above, there was a significant reduction in the frequency of
IFN-γ+ and IL-17A+ cells in the DLNs from EAE mice
treated with rhPDCD5 prophylactically (Fig. 3a, b) andnal cord destruction. EAE mice treated with OVA or rhPDCD5
ing EAE induction and b therapeutically every other day from onset
e independent experiments were performed. Data are means ± SEM
sis was performed using repeated measures two-way ANOVA
0.05. c, d Representative microscopic photographs of spinal cord
treated with OVA or rhPDCD5 (10 mg/kg, i.p.) prophylactically
Fig. 2 Levels of IFN-γ and IL-17A are downregulated in EAE mice treated with rhPDCD5. a, b Serum samples were collected from mice treated
with OVA or rhPDCD5 prophylactically and therapeutically on day 25 after immunization, and cytokine concentrations were determined by ELISA.
Data are means ± SEM (n = 10). c, d Draining lymph node cells were obtained from indicated mice and cultured with or without MOG35–55 (20 μg/ml)
for 48 h, and the cytokine levels in the culture supernatants were determined by ELISA. Data are means ± SEM (n = 10). *P < 0.05, **P < 0.005
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OVA. PDCD5 transgenic mice have increased numbers of
Foxp3+ CD4+ regulatory T cells, which protect the mice
from EAE [33]. We thus examined whether the recombin-
ant protein rhPDCD5 protects via regulatory T cells, and
our results showed that there was no apparent increase in
the number and proportion of regulatory T cells during the
EAE course, indicating that it is unlikely that the reduced
clinical scores of EAE mice treated with rhPDCD5 protein
were due to the enhanced regulatory T cells response.
Taken together, our data suggest that in vivo rhPDCD5
ameliorates EAE through downregulating the population
of inflammatory Th1/Th17 cells.
rhPDCD5 inhibits proliferation of lymphocytes and
induces apoptosis of MOG35–55 specific CD4
+ T cells
in vivo
Lymphocyte responses to MOG35–55 in DLNs from mice
treated with OVA and rhPDCD5 prophylactically and
therapeutically are shown in Fig. 4a, b. We observed that
[3H]-thymidine uptake was significantly lower in cells
from mice treated with rhPDCD5 prophylactically and
therapeutically in vivo, and there was no significant
difference in the medium controls between them. This
experiment indicates that pretreatment with rhPDCD5
in vivo inhibits the lymphocyte proliferation activated by
MOG35–55.Given the pro-apoptotic function of PDCD5, we next
monitored CD4+ T cell apoptosis using FITC-Annexin V
staining and flow cytometry analysis. Single cell suspen-
sions were prepared from the DLNs of EAE mice at day
25 after immunization and stained for CD4 and AV by
FACS. There was a significant increase in the frequency
of CD4+AV+ cells in the DLNs from EAE mice treated
with rhPDCD5 prophylactically (Fig. 5a, b) and thera-
peutically (Fig. 5c, d) compared with mice treated by
OVA. Without MOG35–55 stimulation, the percentage of
CD4+ T cell apoptosis was not different between EAE
mice treated with OVA or rhPDCD5. In normal mice
without EAE, rhPDCD5 did not induce apoptosis and
did not alter the number of lymphocytes. RhPDCD5
treatment only induced apoptosis of MOG-activated T
cells but not normal T cells. It is likely that rhPDCD5-
induced cell death may explain the lower level of inflam-
mation and downregulation of Th1/Th17 cells in EAE
mice treated with rhPDCD5 prophylactically and thera-
peutically in vivo.
rhPDCD5 induces activation of caspase-3, enhances the
expression of Bax, and suppresses the expression of Bcl-2
To address the mechanism of rhPDCD5-induced cell
death, cells were extracted from DLNs at day 25 post
immunization and analyzed by Western blotting the ex-
pression of Bcl-2, Bax and activated caspase-3. As shown
Fig. 3 rhPDCD5 treatment reduces Th1/Th17 response in EAE mice in vivo. a, c DLN cells were collected from EAE mice treated with OVA or
rhPDCD5 (10 mg/kg i.p.) prophylactically and therapeutically at day 25 after immunization and stimulated with PMA plus ionomycin in the
presence of brefeldin A for 4 h. CD4+IFN-γ+ T cells and CD4+IL-17A+ cells were measured by flow cytometry. b, d Percentages of CD4+IFN-γ+
T cells and CD4+IL-17A+ T cells are shown as means ± SEM (n = 10). *P < 0.05, **P < 0.005
Fig. 4 rhPDCD5 inhibits lymphocyte proliferation to MOG. Lymphocytes were obtained from DLNs in EAE mice treated with OVA or rhPDCD5
prophylactically (a) and therapeutically (b) at day 25 after immunization, cultured with or without MOG35–55 (20 μg/ml) for 48 h. Cell proliferation
was determined by the uptake of [3H] incorporation. Data are means ± SEM (n = 8). ***P < 0.0005
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Fig. 5 rhPDCD5 induces apoptosis of MOG-stimulated T cells in vivo. a, c Lymphocytes were obtained from DLNs in EAE mice treated with OVA
or rhPDCD5 prophylactically and therapeutically at day 25 after immunization, cultured with or without MOG35–55 (20 μg/ml) for 48 h. Cellular
apoptosis was analyzed by FITC-Annexin V plus anti-CD4-PE staining and flow cytometry. b, d Percentages of CD4+AV+ T cells are shown as
means ± SEM (n = 10). **P < 0.005
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Bax and activated caspase-3 were detected in lympho-
cytes pretreated with rhPDCD5 prophylactically and
therapeutically in vivo.
rhPDCD5 induces apoptosis of MOG35–55 specific CD4
+
T cells
Single cell suspensions from DLNs of EAE mice at day 12
after immunization were stimulated with MOG35–55 and
increasing concentrations of rhPDCD5 for 48 h. Cells
were then stained with CD4 and AV by FACS. A dose-
dependent effect was seen in rhPDCD5-induced MOG-
specific apoptosis of CD4+ T cells (Fig. 7a). The same
treated lymphocytes were collected and then examined for
the expression of PDCD5 by Western blot analysis. As
shown in Fig. 7b, the expression of PDCD5 mRNA and
protein level increased along with the increase of cell
apoptosis, indicating that endogenous PDCD5 is upregu-
lated when lymphocytes undergo apoptosis.
To directly demonstrate whether rhPDCD5 could in-
duce apoptosis of MOG-reactive CD4+ T, CD4+ T cells
isolated from MOG-immunized donor mice were re-
stimulated with MOG together with rhPDCD5 in vitro
and then adoptively transferred to naïve mice to induce
passive EAE. Notably, rhPDCD5 (20 μg/ml) pretreated
CD4+ T cells induced a less severe EAE symptom than
CD4+ T cells re-stimulated by MOG only (Fig. 7c).These results indicate that rhPDCD5 acts by increasing
apoptosis of MOG-reactive CD4+ T cells.
Discussion
Data presented in this study demonstrate that treatment
of EAE mice with rhPDCD5 shows benefits at both clin-
ical and pathological levels. The protection against EAE is
not only due to downregulation of Th1/Th17 cells but
also attributable to higher levels of activation-induced cell
death in T cells, with both prophylactic and therapeutic
rhPDCD5 treatment regimens in vivo. Furthermore, we
show that the expression of Bax and caspase 3 is increased
and expression of Bcl-2 is decreased in lymphocytes
treated by rhPDCD5 in vivo. In addition, rhPDCD5 in-
duces apoptosis of myelin-specific CD4+ T cells in vitro.
EAE is a well-known model of MS, the most common
chronic neuroinflammatory, demyelinating disease of the
CNS in humans. In the past, EAE was considered to be
a Th1-driven disease. However, the discovery of a third
major helper T cell subclass, called Th17 cells, has sub-
stantially increased our understanding of the cellular
basis of EAE pathogenesis [11, 34]. Both Th1 and Th17
cells have been shown to be capable of driving EAE, but
neither cell type can exclusively induce pathogenesis of
the same extent without a contribution from the other
[35–37]. In the context of the present study, it is likely
that the reduced clinical symptom and pathology in EAE
Fig. 6 The expression of caspase-3, BAX, and BCL-2 in EAE mice. a, b Lymphocytes were collected from DLNs in EAE mice treated with OVA or
rhPDCD5 (10 mg/kg i.p.) prophylactically and therapeutically at day 25 after immunization. Cell lysate was examined for the expression of
procaspase-3 (inactive form), cleaved caspase 3 (active form), BAX, and BCL-2 by Western blot analysis. Actin was used as a housekeeping protein,
and the gels have been run under the same experimental conditions. The relative levels of procaspase 3/cleaved caspase 3 were quantified by
densitometric analysis and normalized with Actin. Data are means ± SEM (n = 4). Statistical differences were evaluated with Student t-test. *P < 0.05
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peutically is due to the decreased Th1/Th17 cell fre-
quency, accompanied by a reduction of pro-
inflammatory cytokines in the serum. PDCD5 has been
implicated in the downregulation of Th1 and Th17 cells
in PDCD5 transgenic mice [33]. This study is the first to
show that exogenous recombinant human PDCD5 pro-
tein can induce the downregulation of Th1/Th17 cells
in vivo. The polarization of naïve T cells into Th1/Th17
cells depends on the cytokine milieu in the tissue.
Whether rhPDCD5 affects the cytokine milieu or dir-
ectly enters the lymphocytes to inhibit the differentiation
of Th1/Th17 remains unclear.
During the course of EAE, inflammatory lymphocytes
enter the CNS and elicit variable degrees of demyelin-
ation and inflammation [38]. The ongoing inflammation
is manifested by clinical signs, such as paresis and par-
alysis of the limbs. In the EAE mouse model, factors
leading to increased apoptosis of activated T cells havebeen shown to decrease disease severity [21, 22], while
factors that decrease the apoptosis of activated T cells
increase disease severity [18, 19]. At any time during
EAE, the magnitude of T cell responses against myelin
antigen involves the balance between an increasing num-
ber of myelin-specific lymphocytes due to cell division
and loss of T cells by activation-induced cell death. Dur-
ing EAE recovery, apoptosis is a leading mechanism for
the clearance of CNS infiltrating cells [39]. Our experi-
ments show that rhPDCD5 is involved in the apoptosis
of activated CD4+ lymphocytes as we observe an in-
crease in the proportion of MOG35–55 activated CD4
+
lymphocytes undergoing apoptosis in rhPDCD5-treated
mice compared to OVA-treated mice. Moreover,
rhPDCD5 induces apoptosis of myelin-specific T cells in
a dose-dependent manner in vitro, accompanied by
upregulation of endogenous PDCD5 in lymphocytes, in-
dicating that PDCD5 is upregulated when lymphocytes
undergo apoptosis. Whether rhPDCD5 selectively enters
Fig. 7 rhPDCD5 induces apoptosis of MOG-specific T cells. a Apoptosis of CD4+ T cells was determined and quantified by the percentage of AV
positive cells showing an increase in a dose-dependent manner, and representative histograms are shown. b Lymphocytes treated with rhPDCD5
were examined the expression of PDCD5 mRNA and protein levels by RT-PCR and Western blot analysis. Gels have been run under the same
experimental conditions. c DLN lymphocytes and splenocytes isolated from donor mice 12 days post-immunization were re-stimulated with MOG
and rhPDCD5, and 3 × 106/ml CD4+ T cells were transferred into irradiated naïve mice to induce passive EAE. Mice were then monitored daily for
mean clinical score. Two independent adoptive transfer experiments were performed. Data are means ± SEM from mice treated with MOG (n = 8)
or MOG+ rhPDCD5 (n = 8). Statistical analysis was performed using repeated measures two-way ANOVA followed by Bonferroni post hoc tests to
compare replicate by time. *P < 0.05
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that warrants further investigation. It has been shown
that exogenous rhPDCD5 promotes apoptosis in a
number of tumor cells [23, 30–32, 40], but to our
knowledge, this study is the first to demonstrate that
rhPDCD5 induces apoptosis of antigen-activated ma-
ture T lymphocytes.
Apoptosis is a developmentally and physiologically
critical process that is tightly regulated by the coordi-
nated action of diverse extracellular cues and intracel-
lular signaling molecules. Specifically, the Bcl-2 family
of proteins has been shown to play important roles in
several different pathways affected by apoptosis, with
the ratio of Bax/Bcl-2 being critical for the induction of
apoptosis. Bcl-2 is an anti-apoptotic protein that pre-
vents the initiation of apoptosis by blocking the efflux
of cytochrome c from mitochondria [41]. Overexpres-
sion of Bcl-2 in lymphocytes suppresses apoptosis and
promotes development of T and B cells [42]. Further-
more, it has been shown that overexpression of Bcl-2
delays caspase-3 activation and rescues cerebellar de-
generation in prion-deficient mice [43]. Caspase-3 is a
crucial mediator that catalyzes the cleavage of several
key proteins to trigger apoptosis [44]. Using Western
blot analysis of lymphocytes of EAE mice, we showed
that expression of Bax and activated caspase-3 was
increased but expression of Bcl-2 was decreased in lym-
phocytes treated with rhPDCD5 in vivo, in agreement
with an earlier report [30].
In summary, our study demonstrates that rhPDCD5 has
a protective role in EAE, and rhPDCD5 is a potential
therapeutic agent for MS. The beneficial effects of
rhPDCD5 are associated with downregulation of Th1/
Th17 response and activation-induced T cell death. For
future studies, it would be interesting to further investi-
gate the exact function of rhPDCD5 in the CNS, the direct
effect of rhPDCD5 on demyelination and remyelination,
and the precise mechanism by which rhPDCD5 acts in
the experimental model of MS.Competing interests
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